40 results on '"Marques, FZ"'
Search Results
2. Breaking the Barrier: The Role of Gut Epithelial Permeability in the Pathogenesis of Hypertension.
- Author
-
Snelson M, Vanuytsel T, and Marques FZ
- Subjects
- Humans, Animals, Gastrointestinal Microbiome physiology, Biomarkers metabolism, Gastrointestinal Tract physiopathology, Hypertension physiopathology, Permeability, Intestinal Mucosa physiopathology, Intestinal Mucosa metabolism
- Abstract
Purpose of the Review: To review what intestinal permeability is and how it is measured, and to summarise the current evidence linking altered intestinal permeability with the development of hypertension., Recent Findings: Increased gastrointestinal permeability, directly measured in vivo, has been demonstrated in experimental and genetic animal models of hypertension. This is consistent with the passage of microbial substances to the systemic circulation and the activation of inflammatory pathways. Evidence for increased gut permeability in human hypertension has been reliant of a handful of blood biomarkers, with no studies directly measuring gut permeability in hypertensive cohorts. There is emerging literature that some of these putative biomarkers may not accurately reflect permeability of the gastrointestinal tract. Data from animal models of hypertension support they have increased gut permeability; however, there is a dearth of conclusive evidence in humans. Future studies are needed that directly measure intestinal permeability in people with hypertension., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
3. The gut-immune axis during hypertension and cardiovascular diseases.
- Author
-
Dinakis E, O'Donnell JA, and Marques FZ
- Subjects
- Humans, Animals, Dysbiosis immunology, Inflammation immunology, Inflammation metabolism, Gastrointestinal Microbiome physiology, Hypertension immunology, Hypertension physiopathology, Hypertension microbiology, Cardiovascular Diseases immunology, Cardiovascular Diseases microbiology
- Abstract
The gut-immune axis is a relatively novel phenomenon that provides mechanistic links between the gut microbiome and the immune system. A growing body of evidence supports it is key in how the gut microbiome contributes to several diseases, including hypertension and cardiovascular diseases (CVDs). Evidence over the past decade supports a causal link of the gut microbiome in hypertension and its complications, including myocardial infarction, atherosclerosis, heart failure, and stroke. Perturbations in gut homeostasis such as dysbiosis (i.e., alterations in gut microbial composition) may trigger immune responses that lead to chronic low-grade inflammation and, ultimately, the development and progression of these conditions. This is unsurprising, as the gut harbors one of the largest numbers of immune cells in the body, yet is a phenomenon not entirely understood in the context of cardiometabolic disorders. In this review, we discuss the role of the gut microbiome, the immune system, and inflammation in the context of hypertension and CVD, and consolidate current evidence of this complex interplay, whilst highlighting gaps in the literature. We focus on diet as one of the major modulators of the gut microbiota, and explain key microbial-derived metabolites (e.g., short-chain fatty acids, trimethylamine N-oxide) as potential mediators of the communication between the gut and peripheral organs such as the heart, arteries, kidneys, and the brain via the immune system. Finally, we explore the dual role of both the gut microbiome and the immune system, and how they work together to not only contribute, but also mitigate hypertension and CVD., (© 2024 The Author(s). Acta Physiologica published by John Wiley & Sons Ltd on behalf of Scandinavian Physiological Society.)
- Published
- 2024
- Full Text
- View/download PDF
4. Recommendations for the Use of Dietary Fiber to Improve Blood Pressure Control.
- Author
-
Jama HA, Snelson M, Schutte AE, Muir J, and Marques FZ
- Subjects
- Humans, Cardiovascular Diseases prevention & control, Life Style, Male, Female, Adult, Blood Pressure physiology, Blood Pressure drug effects, Dietary Fiber administration & dosage, Hypertension diet therapy, Hypertension prevention & control, Hypertension physiopathology
- Abstract
According to several international, regional, and national guidelines on hypertension, lifestyle interventions are the first-line treatment to lower blood pressure (BP). Although diet is one of the major lifestyle modifications described in hypertension guidelines, dietary fiber is not specified. Suboptimal intake of foods high in fiber, such as in Westernized diets, is a major contributing factor to mortality and morbidity of noncommunicable diseases due to higher BP and cardiovascular disease. In this review, we address this deficiency by examining and advocating for the incorporation of dietary fiber as a key lifestyle modification to manage elevated BP. We explain what dietary fiber is, review the existing literature that supports its use to lower BP and prevent cardiovascular disease, describe the mechanisms involved, propose evidence-based target levels of fiber intake, provide examples of how patients can achieve the recommended targets, and discuss outstanding questions in the field. According to the evidence reviewed here, the minimum daily dietary fiber for adults with hypertension should be >28 g/day for women and >38 g/day for men, with each extra 5 g/day estimated to reduce systolic BP by 2.8 mm Hg and diastolic BP by 2.1 mm Hg. This would support a healthy gut microbiota and the production of gut microbiota-derived metabolites called short-chain fatty acids that lower BP. Awareness about dietary fiber targets and how to achieve them will guide medical teams on better educating patients and empowering them to increase their fiber intake and, as a result, lower their BP and cardiovascular disease risk., Competing Interests: Disclosures J. Muir works in a department that financially benefits from the sales of a digital application, booklets, cookbooks, online courses, and a food certification program on the low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet. Funds raised from these activities contribute to the research of the Department of Gastroenterology and Monash University. The salary of J. Muir is now 100% paid by these commercial activities. The other authors report no conflicts.
- Published
- 2024
- Full Text
- View/download PDF
5. Prospects for Leveraging the Microbiota as Medicine for Hypertension.
- Author
-
Durgan DJ, Zubcevic J, Vijay-Kumar M, Yang T, Manandhar I, Aryal S, Muralitharan RR, Li HB, Li Y, Abais-Battad JM, Pluznick JL, Muller DN, Marques FZ, and Joe B
- Subjects
- Humans, Blood Pressure, Hypertension, Microbiota
- Abstract
Competing Interests: Disclosures None.
- Published
- 2024
- Full Text
- View/download PDF
6. Dietary fiber intake impacts gut bacterial and viral populations in a hypertensive mouse model.
- Author
-
Avellaneda-Franco L, Xie L, Nakai M, Barr JJ, and Marques FZ
- Subjects
- Animals, Mice, Male, Angiotensin II metabolism, Genome, Viral, Gastrointestinal Microbiome, Dietary Fiber administration & dosage, Hypertension virology, Mice, Inbred C57BL, Bacteria classification, Bacteria genetics, Bacteria isolation & purification, Bacteriophages physiology, Bacteriophages genetics, Disease Models, Animal
- Abstract
The gut microbiome is an emerging factor in preventing hypertension, yet the influence of gut bacteriophages, viruses infecting bacteria, on this condition remains unclear. Bacteriophage-bacteria interactions, which impact the gut microbiome, are influenced differentially by temperate and virulent bacteriophages. However, the standard technique for studying viral populations, viral-like particles (VLPs)-metagenomes, often overlook prophages, the intracellular stage of temperate bacteriophages, creating a knowledge gap. To address this, we investigated alterations in extracellular and intracellular bacteriophages, alongside bacterial populations, in the angiotensin II-hypertension model. We sequenced VLPs and bulk DNA from cecal-colonic samples collected from male C57BL/6J mice implanted with minipumps containing saline or angiotensin II. We assembled 106 bacterial and 816 viral genomes and found that gut viral and bacterial populations remained stable between hypertensive and normotensive mice. A higher number of temperate viruses were observed across all treatments. Although temperate viruses outnumbered virulent viruses, sequencing of both VLPs and bulk revealed that virions from virulent viruses were more abundant in the murine gut. We then evaluated the impact of low- and high-fiber intake on gut microbiome composition in the angiotensin II model. Fiber intake significantly influenced the gut microbiome composition and hypertension development. Mice receiving high-fiber had lower blood pressure, a higher bacterial-encoded carbohydrate-associated enzyme, and a higher total relative abundance of temperate viruses than those receiving low-fiber. Our findings suggest that phages are not associated with hypertension development in the angiotensin II model. However, they support a complex diet-bacteria/phage interaction that may be involved in blood pressure regulation.
- Published
- 2024
- Full Text
- View/download PDF
7. Content and delivery preferences for information to support the management of high blood pressure.
- Author
-
Chapman N, Marques FZ, Picone DS, Adji A, Broughton BRS, Dinh QN, Gabb G, Lambert GW, Mihailidou AS, Nelson MR, Stowasser M, Schlaich M, Schultz MG, Mynard JP, and Climie RE
- Subjects
- Adult, Humans, Female, Male, Australia, Surveys and Questionnaires, Blood Pressure, General Practitioners, Hypertension diagnosis, Hypertension drug therapy
- Abstract
Blood pressure(BP) management interventions have been shown to be more effective when accompanied by appropriate patient education. As high BP remains poorly controlled, there may be gaps in patient knowledge and education. Therefore, this study aimed to identify specific content and delivery preferences for information to support BP management among Australian adults from the general public. Given that BP management is predominantly undertaken by general practitioners(GPs), information preferences to support BP management were also ascertained from a small sample of Australian GPs. An online survey of adults was conducted to identify areas of concern for BP management to inform content preferences and preferred format for information delivery. A separate online survey was also delivered to GPs to determine preferred information sources to support BP management. Participants were recruited via social media. General public participants (n = 465) were mostly female (68%), >60 years (57%) and 49% were taking BP-lowering medications. The management of BP without medications, and role of lifestyle in BP management were of concern among 30% and 26% of adults respectively. Most adults (73%) preferred to access BP management information from their GP. 57% of GPs (total n = 23) preferred information for supporting BP management to be delivered via one-page summaries. This study identified that Australian adults would prefer more information about the management of BP without medications and via lifestyle delivered by their GP. This could be achieved by providing GPs with one-page summaries on relevant topics to support patient education and ultimately improve BP management., (© 2022. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
8. Lifestyle management of hypertension: International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension.
- Author
-
Charchar FJ, Prestes PR, Mills C, Ching SM, Neupane D, Marques FZ, Sharman JE, Vogt L, Burrell LM, Korostovtseva L, Zec M, Patil M, Schultz MG, Wallen MP, Renna NF, Islam SMS, Hiremath S, Gyeltshen T, Chia YC, Gupta A, Schutte AE, Klein B, Borghi C, Browning CJ, Czesnikiewicz-Guzik M, Lee HY, Itoh H, Miura K, Brunström M, Campbell NRC, Akinnibossun OA, Veerabhadrappa P, Wainford RD, Kruger R, Thomas SA, Komori T, Ralapanawa U, Cornelissen VA, Kapil V, Li Y, Zhang Y, Jafar TH, Khan N, Williams B, Stergiou G, and Tomaszewski M
- Subjects
- Humans, Life Style, Blood Pressure, Hypertension prevention & control, Hypertension complications, Cardiovascular Diseases etiology, Heart Failure complications
- Abstract
Hypertension, defined as persistently elevated systolic blood pressure (SBP) >140 mmHg and/or diastolic blood pressure (DBP) at least 90 mmHg (International Society of Hypertension guidelines), affects over 1.5 billion people worldwide. Hypertension is associated with increased risk of cardiovascular disease (CVD) events (e.g. coronary heart disease, heart failure and stroke) and death. An international panel of experts convened by the International Society of Hypertension College of Experts compiled lifestyle management recommendations as first-line strategy to prevent and control hypertension in adulthood. We also recommend that lifestyle changes be continued even when blood pressure-lowering medications are prescribed. Specific recommendations based on literature evidence are summarized with advice to start these measures early in life, including maintaining a healthy body weight, increased levels of different types of physical activity, healthy eating and drinking, avoidance and cessation of smoking and alcohol use, management of stress and sleep levels. We also discuss the relevance of specific approaches including consumption of sodium, potassium, sugar, fibre, coffee, tea, intermittent fasting as well as integrated strategies to implement these recommendations using, for example, behaviour change-related technologies and digital tools., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
9. Novel mechanisms of salt-sensitive hypertension.
- Author
-
Vogt L, Marques FZ, Fujita T, Hoorn EJ, and Danser AHJ
- Subjects
- Humans, Aldosterone, Blood Pressure, Mineralocorticoid Receptor Antagonists pharmacology, Sodium Chloride, Dietary adverse effects, Hypertension genetics, Receptors, Mineralocorticoid
- Abstract
A high dietary sodium-consumption level is considered the most important lifestyle factor that can be modified to help prevent an increase in blood pressure and the development of hypertension. Despite numerous studies over the past decades, the pathophysiology explaining why some people show a salt-sensitive blood pressure response and others do not is incompletely understood. Here, a brief overview of the latest mechanistic insights is provided, focusing on the mononuclear phagocytic system and inflammation, the gut-kidney axis, and epigenetics. The article also discusses the effects of 3 types of novel drugs on salt-sensitive hypertension-sodium-glucose cotransporter 2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, and aldosterone synthase inhibitors. The conclusion is that besides kidney-centered mechanisms, vasoconstrictor mechanisms are also relevant for both the understanding and treatment of this blood pressure phenotype., (Crown Copyright © 2023. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
10. Challenging the status quo: a case for the lack of gut microbiota exacerbating hypertensive end-organ damage.
- Author
-
Xu C and Marques FZ
- Subjects
- Humans, Blood Pressure, Inflammation, Gastrointestinal Microbiome, Hypertension diagnosis, Hypertension physiopathology
- Abstract
Competing Interests: Conflict of interest: None declared.
- Published
- 2023
- Full Text
- View/download PDF
11. Stagnating rates of blood pressure control in Australia: insights from opportunistic screening of 10 046 participants of the May Measurement Month campaigns.
- Author
-
Carnagarin R, Nolde JM, Yang J, Marques FZ, Picone DS, Lambert GW, Beaney T, Poulter NR, Schutte AE, Reid CM, Brockman D, and Schlaich MP
- Subjects
- Adult, Humans, Blood Pressure, Australia epidemiology, Mass Screening, Antihypertensive Agents therapeutic use, Hypertension diagnosis, Hypertension drug therapy, Hypertension epidemiology
- Abstract
Background: Raised blood pressure (BP) remains the single most important modifiable risk factor contributing to cardiovascular and all-cause mortality in Australia and worldwide. May Measurement Month , a global BP measurement and screening campaign initiated by the International Society of Hypertension and carried out in Australia since its inception in 2017, aimed at obtaining standardized BP measurements from members of the community to increase awareness of high BP and its associated risks., Method: Adults participants (≥18 years) were recruited through opportunistic sampling across Australia during the month of May in 2017, 2018 and 2019. Trained volunteers recorded BP readings in a standardized manner and collected data on demographic, lifestyle factors and comorbidities. Hypertension was defined as SBP of at least 140 mmHg, or DBP of at least 90 mmHg, or taking antihypertensive medication. Data were collated centrally and analysis was carried out using regression models to evaluate the associations between BP and participant characteristics., Results: A total of 10 046 participants were screened, of whom 3097 (31.0%) had hypertension, only 48.5% were aware of their condition and 44.4% were taking antihypertensive medication. Of those taking antihypertensive medication, 53.2% were controlled to less than 140/90 mmHg, whereas the remaining 46.8% of participants had BP of at least 140/90 mmHg suggestive of inadequately treated hypertension., Conclusion: Consecutive data obtained over a 3-year period in Australia demonstrated stagnating awareness, treatment and control rates with the latter two being substantially lower than global rates and those in other high-income countries. Concerted efforts from all stakeholders will be required to help overcome the unacceptably poor rates of BP treatment and control in Australia., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
12. The gut microbiome and hypertension.
- Author
-
O'Donnell JA, Zheng T, Meric G, and Marques FZ
- Subjects
- Animals, Dysbiosis complications, Dysbiosis therapy, Mechanotransduction, Cellular, Blood Pressure, Gastrointestinal Microbiome, Hypertension
- Abstract
A large body of evidence has emerged in the past decade supporting a role for the gut microbiome in the regulation of blood pressure. The field has moved from association to causation in the last 5 years, with studies that have used germ-free animals, antibiotic treatments and direct supplementation with microbial metabolites. The gut microbiome can regulate blood pressure through several mechanisms, including through gut dysbiosis-induced changes in microbiome-associated gene pathways in the host. Microbiota-derived metabolites are either beneficial (for example, short-chain fatty acids and indole-3-lactic acid) or detrimental (for example, trimethylamine N-oxide), and can activate several downstream signalling pathways via G protein-coupled receptors or through direct immune cell activation. Moreover, dysbiosis-associated breakdown of the gut epithelial barrier can elicit systemic inflammation and disrupt intestinal mechanotransduction. These alterations activate mechanisms that are traditionally associated with blood pressure regulation, such as the renin-angiotensin-aldosterone system, the autonomic nervous system, and the immune system. Several methodological and technological challenges remain in gut microbiome research, and the solutions involve minimizing confounding factors, establishing causality and acting globally to improve sample diversity. New clinical trials, precision microbiome medicine and computational methods such as Mendelian randomization have the potential to enable leveraging of the microbiome for translational applications to lower blood pressure., (© 2023. Springer Nature Limited.)
- Published
- 2023
- Full Text
- View/download PDF
13. How Dietary Fibre, Acting via the Gut Microbiome, Lowers Blood Pressure.
- Author
-
Xu C and Marques FZ
- Subjects
- Acetates, Blood Pressure, Butyrates, Dietary Fiber, Fatty Acids, Volatile metabolism, Humans, Propionates, Receptors, G-Protein-Coupled metabolism, Gastrointestinal Microbiome physiology, Hypertension, Hypotension
- Abstract
Purpose of Review: To discuss the interplay behind how a high-fibre diet leads to lower blood pressure (BP) via the gut microbiome., Recent Findings: Compelling evidence from meta-analyses support dietary fibre prevents the development of cardiovascular disease and reduces BP. This relation is due to gut microbial metabolites, called short-chain fatty acids (SCFAs), derived from fibre fermentation. The SCFAs acetate, propionate and butyrate lower BP in independent hypertensive models. Mechanisms are diverse but still not fully understood-for example, they include G protein-coupled receptors, epigenetics, immune cells, the renin-angiotensin system and vasculature changes. Lack of dietary fibre leads to changes to the gut microbiota that drive an increase in BP. The mechanisms involved are unknown. The intricate interplay between fibre, the gut microbiota and SCFAs may represent novel therapeutic approaches for high BP. Other gut microbiota-derived metabolites, produced when fibre intake is low, may hold potential therapeutic applications. Further translational evidence is needed., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
14. Gut Microbiota: Friends or Foes for Blood Pressure-Lowering Drugs.
- Author
-
Zheng T and Marques FZ
- Subjects
- Antihypertensive Agents pharmacology, Antihypertensive Agents therapeutic use, Blood Pressure, Humans, Gastrointestinal Microbiome, Hypertension drug therapy
- Published
- 2022
- Full Text
- View/download PDF
15. Association Between the Gut Microbiome and Their Metabolites With Human Blood Pressure Variability.
- Author
-
Dinakis E, Nakai M, Gill P, Ribeiro R, Yiallourou S, Sata Y, Muir J, Carrington M, Head GA, Kaye DM, and Marques FZ
- Subjects
- Blood Pressure physiology, Blood Pressure Monitoring, Ambulatory methods, Circadian Rhythm physiology, Female, Humans, Male, Gastrointestinal Microbiome, Hypertension
- Abstract
Background: Blood pressure (BP) variability is an independent risk factor for cardiovascular events. Recent evidence supports a role for the gut microbiota in BP regulation. However, whether the gut microbiome is associated with BP variability is yet to be determined. Here, we aimed to investigate the interplay between the gut microbiome and their metabolites in relation to BP variability., Methods: Ambulatory BP monitoring was performed in 69 participants from Australia (55.1% women; mean±SD, 59.8±7.26 years; body mass index, 25.2±2.83 kg/m
2 ). These data were used to determine nighttime dipping, morning BP surge (MBPS) and BP variability as SD. The gut microbiome was determined by 16S ribosomal RNA (rRNA) sequencing and metabolite levels by gas chromatography., Results: We identified specific taxa associated with systolic BP variability, nighttime dipping, and MBPS. Notably, Alistipesfinegoldii and Lactobacillus spp. were only present in participants within the normal ranges of BP variability, MBPS and dipping, while Prevotella spp. and Clostridium spp., were found to be present in extreme dippers and the highest quartiles of BP SD and MBPS. There was a negative association between MBPS and microbial α-diversity (r=-0.244, P =0.046). MBPS was also negatively associated with plasma levels of microbial metabolites called short-chain fatty acids (r=-0.305, P =0.020), particularly acetate (r=-0.311, P =0.017)., Conclusions: Gut microbiome diversity, levels of microbial metabolites, and the bacteria Alistipesfinegoldii and Lactobacillus were associated with lower BP variability and Clostridium and Prevotella with higher BP variability. Thus, our findings suggest the gut microbiome and metabolites may be involved in the regulation of BP variability.- Published
- 2022
- Full Text
- View/download PDF
16. Rodent models of hypertension.
- Author
-
Jama HA, Muralitharan RR, Xu C, O'Donnell JA, Bertagnolli M, Broughton BRS, Head GA, and Marques FZ
- Subjects
- Animals, Female, Inflammation, Pregnancy, Rodentia, Sympathetic Nervous System, Cardiovascular Diseases, Hypertension
- Abstract
Elevated blood pressure (BP), or hypertension, is the main risk factor for cardiovascular disease. As a multifactorial and systemic disease that involves multiple organs and systems, hypertension remains a challenging disease to study. Models of hypertension are invaluable to support the discovery of the specific genetic, cellular and molecular mechanisms underlying essential hypertension, as well as to test new possible treatments to lower BP. Rodent models have proven to be an invaluable tool for advancing the field. In this review, we discuss the strengths and weaknesses of rodent models of hypertension through a systems approach. We highlight the ways how target organs and systems including the kidneys, vasculature, the sympathetic nervous system (SNS), immune system and the gut microbiota influence BP in each rodent model. We also discuss often overlooked hypertensive conditions such as pulmonary hypertension and hypertensive-pregnancy disorders, providing an important resource for researchers. LINKED ARTICLES: This article is part of a themed issue on Preclinical Models for Cardiovascular disease research (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.5/issuetoc., (© 2021 The British Pharmacological Society.)
- Published
- 2022
- Full Text
- View/download PDF
17. Diet-related gut microbial metabolites and sensing in hypertension.
- Author
-
R Muralitharan R and Marques FZ
- Subjects
- Animals, Blood Pressure, Diet, Fatty Acids, Volatile, Humans, Mice, Neoplasm Proteins, Gastrointestinal Microbiome, Hypertension etiology, Receptors, Odorant
- Abstract
Advances in sequencing technology have increased our understanding of the composition of the gut microbiota and their contribution to health and disease states, including in cardiovascular diseases such as hypertension. The gut microbiota is heavily influenced by diet and produce metabolites such as short-chain fatty acids (SCFAs) and trimethylamine-N-oxide (TMAO) from various food sources. SCFAs, such as acetate, propionate, and butyrate, have been shown to have blood pressure, cardiac hypertrophy, and fibrosis lowering properties, while TMAO has been associated with increased risk of major cardiovascular adverse events and mortality. Some of these metabolites have known ligands (for example, SCFA receptors such as GPR41, GPR43, GPR109a, and Olf78 in mice/OR51E2 in humans) which could potentially be manipulated as therapeutic targets for hypertension. In this review, we discuss several types of diet-related gut microbial metabolites and their sensing mechanisms that are relevant for hypertension, and the future directions for the field.
- Published
- 2021
- Full Text
- View/download PDF
18. Microbial Peer Pressure: The Role of the Gut Microbiota in Hypertension and Its Complications.
- Author
-
Muralitharan RR, Jama HA, Xie L, Peh A, Snelson M, and Marques FZ
- Subjects
- Animals, Blood Pressure drug effects, Cardiovascular System metabolism, Humans, Hypertension metabolism, Prebiotics administration & dosage, Probiotics administration & dosage, Blood Pressure physiology, Cardiovascular System physiopathology, Fatty Acids, Volatile metabolism, Gastrointestinal Microbiome physiology, Hypertension physiopathology, Receptors, G-Protein-Coupled metabolism
- Abstract
There is increasing evidence of the influence of the gut microbiota on hypertension and its complications, such as chronic kidney disease, stroke, heart failure, and myocardial infarction. This is not surprising considering that the most common risk factors for hypertension, such as age, sex, medication, and diet, can also impact the gut microbiota. For example, sodium and fermentable fiber have been studied in relation to both hypertension and the gut microbiota. By combining second- and, now, third-generation sequencing with metabolomics approaches, metabolites, such as short-chain fatty acids and trimethylamine N-oxide, and their producers, have been identified and are now known to affect host physiology and the cardiovascular system. The receptors that bind these metabolites have also been explored with positive findings-examples include known short-chain fatty acid receptors, such as G-protein coupled receptors GPR41, GPR43, GPR109a, and OLF78 in mice. GPR41 and OLF78 have been shown to have inverse roles in blood pressure regulation, whereas GPR43 and GPR109A have to date been demonstrated to impact cardiac function. New treatment options in the form of prebiotics (eg, dietary fiber), probiotics (eg, Lactobacillus spp.), and postbiotics (eg, the short-chain fatty acids acetate, propionate, and butyrate) have all been demonstrated to be beneficial in lowering blood pressure in animal models, but the underlying mechanisms remain poorly understood and translation to hypertensive patients is still lacking. Here, we review the evidence for the role of the gut microbiota in hypertension, its risk factors, and cardiorenal complications and identify future directions for this exciting and fast-evolving field.
- Published
- 2020
- Full Text
- View/download PDF
19. Neural suppression of miRNA-181a in the kidney elevates renin expression and exacerbates hypertension in Schlager mice.
- Author
-
Jackson KL, Gueguen C, Lim K, Eikelis N, Stevenson ER, Charchar FJ, Lambert GW, Burke SL, Paterson MR, Marques FZ, and Head GA
- Subjects
- Animals, Denervation, Disease Models, Animal, Hypertension metabolism, Male, Mice, Hypertension etiology, Kidney metabolism, MicroRNAs metabolism, Renin metabolism
- Abstract
BPH/2J mice are a genetic model of hypertension with overactivity of the sympathetic nervous system (SNS) and renin-angiotensin system (RAS). BPH/2J display higher renal renin mRNA and low levels of its negative regulator microRNA-181a (miR-181a). We hypothesise that high renal SNS activity may reduce miR-181a expression, which contributes to elevated RAS activity and hypertension in BPH/2J. Our aim was to determine whether in vivo administration of a renal-specific miR-181a mimic or whether renal denervation could increase renal miR-181a abundance to reduce renal renin mRNA, RAS activity and hypertension in BPH/2J mice. Blood pressure (BP) in BPH/2J and normotensive BPN/3J mice was measured via radiotelemetry probes. Mice were administered miR-181a mimic or a negative control (1-25 nmol, i.v., n = 6-10) with BP measured for 48 h after each dose or they underwent renal denervation or sham surgery (n = 7-9). Injection of 5-25 nmol miR-181a mimic reduced BP in BPH/2J mice after 36-48 h (-5.3 ± 1.8, -6.1 ± 1.9 mmHg, respectively, P < 0.016). Treatment resulted in lower renal renin and inflammatory marker (TLR4) mRNA levels in BPH/2J. The mimic abolished the hypotensive effect of blocking the RAS with enalaprilat (P < 0.01). No differences between mimic or vehicle were observed in BPN/3J mice except for a higher level of renal angiotensinogen in the mimic-treated mice. Renal miR-181a levels that were lower in sham BPH/2J mice were greater following renal denervation and were thus similar to those of BPN/3J. Our findings suggest that the reduced renal miR-181a may partially contribute to the elevated BP in BPH/2J mice, through an interaction between the renal sympathetic nerves and miR-181a regulation of the RAS.
- Published
- 2020
- Full Text
- View/download PDF
20. The Emerging Role of Gut Dysbiosis in Cardio-metabolic Risk Factors for Heart Failure.
- Author
-
Sata Y, Marques FZ, and Kaye DM
- Subjects
- Dysbiosis complications, Humans, Risk Factors, Gastrointestinal Microbiome, Heart Failure etiology, Hypertension
- Abstract
Purpose of Review: To summarize the recent evidence that supports a role for the gut microbiota, microbiota-derived metabolites, and dysbiosis on cardiovascular risk factors, and to discuss the neuro-cardio-metabolic mechanisms that link gut microbiota and heart failure., Recent Findings: There is growing evidence that the gut microbiota communicates with and impacts the cardiovascular system, contributing to the development of heart failure once it becomes out of balance (i.e. gut dysbiosis). The exact mechanisms of how the gut microbiota influences cardiovascular outcomes are not fully understood, but immune dysregulation and disturbance of neuro-enteroendocrine hormones seem to be involved. The disturbances in the gut microbiota influence the progression of several risk factors for heart failure, including atherosclerosis, obesity, diabetes, kidney disease and hypertension. In turn, these conditions also act to regulate the gut microbiota through the deterioration of the integrity of the intestinal barrier and the release of neurotransmitters and gastrointestinal hormones. In normal and healthy physiological conditions, these interactions are homeostatic and tightly controlled. However, a combination of environmental exposures (e.g. antibiotics use and Western diet) and the host's intrinsic conditions (e.g. genetics and fluid status) can result in the breakdown of intestinal homeostasis and further progression of cardiovascular risk factors, which lead to the development of heart failure. Manipulation of the gut microbiota may have the potential to improve cardiovascular outcomes by ameliorating immune system dysregulation, enteroendocrine disruptions, and neurohormonal activation in patients with cardiovascular risk factors for heart failure.
- Published
- 2020
- Full Text
- View/download PDF
21. Highlights from the International Society of Hypertension's New Investigators Network during 2019.
- Author
-
Kruger R, Brunström M, Burger D, Charchar F, Climie R, Mirabito Colafella KM, Kempny P, Korostovtseva L, Marques FZ, Picone D, Romero C, Steckelings UM, Velkoska E, Wainford R, Wynne BM, and Zanuzzi MG
- Subjects
- Female, Humans, Physicians, Social Media, Hypertension, Leadership, Mentors, Research
- Abstract
: The New Investigators Committee (NIC) of the International Society of Hypertension (ISH) is a dynamic group of junior doctors and scientists, actively involved in various society activities. This report highlights the events (scientific meetings and summer schools) and activities (social media, mentorship and networking) during 2019 including May Measurement Month and collaborative efforts with the ISH Women in Hypertension Research Committee (WiHRC). The ISH NIC is proud to sponsor awards for outstanding work by junior and emerging researchers at hypertension conferences and also provides opportunities to showcase their work on our social media features such as 'Our Fellows Work' and the New Investigator Spotlight of the month. In 2020, the ISH NIC aims to promote women in leadership roles and to foster strong collaborations with and between society committees and other scientific organizations.
- Published
- 2020
- Full Text
- View/download PDF
22. Deficiency of Prebiotic Fiber and Insufficient Signaling Through Gut Metabolite-Sensing Receptors Leads to Cardiovascular Disease.
- Author
-
Kaye DM, Shihata WA, Jama HA, Tsyganov K, Ziemann M, Kiriazis H, Horlock D, Vijay A, Giam B, Vinh A, Johnson C, Fiedler A, Donner D, Snelson M, Coughlan MT, Phillips S, Du XJ, El-Osta A, Drummond G, Lambert GW, Spector TD, Valdes AM, Mackay CR, and Marques FZ
- Subjects
- Animals, Male, Mice, Mice, Knockout, Receptors, G-Protein-Coupled genetics, Dietary Fiber deficiency, Fatty Acids, Volatile metabolism, Gastrointestinal Microbiome, Hypertension genetics, Hypertension metabolism, Hypertension microbiology, Hypertension pathology, Intestinal Mucosa metabolism, Intestinal Mucosa microbiology, Intestinal Mucosa pathology, Prebiotics, Receptors, G-Protein-Coupled metabolism, Signal Transduction
- Abstract
Background: High blood pressure (BP) continues to be a major, poorly controlled but modifiable risk factor for cardiovascular death. Among key Western lifestyle factors, a diet poor in fiber is associated with prevalence of high BP. The impact of lack of prebiotic fiber and the associated mechanisms that lead to higher BP are unknown. Here we show that lack of prebiotic dietary fiber leads to the development of a hypertensinogenic gut microbiota, hypertension and its complications, and demonstrate a role for G-protein coupled-receptors (GPCRs) that sense gut metabolites., Methods: One hundred seventy-nine mice including C57BL/6J, gnotobiotic C57BL/6J, and knockout strains for GPR41, GPR43, GPR109A, and GPR43/109A were included. C57BL/6J mice were implanted with minipumps containing saline or a slow-pressor dose of angiotensin II (0.25 mg·kg
-1 ·d-1 ). Mice were fed diets lacking prebiotic fiber with or without addition of gut metabolites called short-chain fatty acids ([SCFA)] produced during fermentation of prebiotic fiber in the large intestine), or high prebiotic fiber diets. Cardiac histology and function, BP, sodium and potassium excretion, gut microbiome, flow cytometry, catecholamines and methylation-wide changes were determined., Results: Lack of prebiotic fiber predisposed mice to hypertension in the presence of a mild hypertensive stimulus, with resultant pathological cardiac remodeling. Transfer of a hypertensinogenic microbiota to gnotobiotic mice recapitulated the prebiotic-deprived hypertensive phenotype, including cardiac manifestations. Reintroduction of SCFAs to fiber-depleted mice had protective effects on the development of hypertension, cardiac hypertrophy, and fibrosis. The cardioprotective effect of SCFAs were mediated via the cognate SCFA receptors GPR43/GPR109A, and modulated L-3,4-dihydroxyphenylalanine levels and the abundance of T regulatory cells regulated by DNA methylation., Conclusions: The detrimental effects of low fiber Westernized diets may underlie hypertension, through deficient SCFA production and GPR43/109A signaling. Maintaining a healthy, SCFA-producing microbiota is important for cardiovascular health.- Published
- 2020
- Full Text
- View/download PDF
23. Don't Take It With a Pinch of Salt: How Sodium Increases Blood Pressure via the Gut Microbiota.
- Author
-
Jama HA and Marques FZ
- Subjects
- Blood Pressure, Corticosterone, Humans, Sodium, Sodium Chloride, Dietary adverse effects, Gastrointestinal Microbiome, Hypertension
- Published
- 2020
- Full Text
- View/download PDF
24. The effect of diet on hypertensive pathology: is there a link via gut microbiota-driven immunometabolism?
- Author
-
Jama HA, Beale A, Shihata WA, and Marques FZ
- Subjects
- Animals, Bacteria metabolism, Cardiovascular System metabolism, Cardiovascular System physiopathology, Humans, Hypertension metabolism, Hypertension microbiology, Hypertension physiopathology, Immune System metabolism, Immune System physiopathology, Inflammation metabolism, Inflammation microbiology, Inflammation physiopathology, Signal Transduction, Bacteria immunology, Blood Pressure, Cardiovascular System immunology, Diet adverse effects, Energy Metabolism immunology, Gastrointestinal Microbiome immunology, Hypertension immunology, Immune System immunology, Immunomodulation, Inflammation immunology
- Abstract
Over the past decade, the immune system has emerged as an important component in the aetiology of hypertension. There has been a blooming interest in the contribution of the gut microbiota, the microbes that inhabit our small and large intestine, to blood pressure (BP) regulation. The gastrointestinal tract houses the largest number of immune cells in our body, thus, it is no surprise that its microbiota plays an important functional role in the appropriate development of the immune system through a co-ordinated sequence of events leading to immune tolerance of commensal bacteria. Importantly, recent evidence supports that the gut microbiota can protect or promote the development of experimental hypertension and is likely to have a role in human hypertension. One of the major modulators of the gut microbiota is diet: diets that emphasize high intake of fermentable fibre, such as the Mediterranean diet and the Dietary Approaches to Stop Hypertension, promote expansion of protective microbes that release gut metabolites such as short-chain fatty acids, which are immune-, BP-, and cardio-protective, likely acting through G-coupled protein receptors. In contrast, diets lacking fibre or high in salt and fat, such as the Western diet, reduce prevalence of commensal microbial species and support a pathogenic and pro-inflammatory environment, including the release of the pro-atherosclerotic trimethylamine N-oxide. Here, we review the current understanding of the gut microbiota-driven immune dysfunction in both experimental and clinical hypertension, and how these changes may be addressed through dietary interventions., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
25. Renal nerves contribute to hypertension in Schlager BPH/2J mice.
- Author
-
Gueguen C, Jackson KL, Marques FZ, Eikelis N, Phillips S, Stevenson ER, Charchar FJ, Lambert GW, Davern PJ, and Head GA
- Subjects
- Animals, Antihypertensive Agents pharmacology, Arterial Pressure, Denervation, Enalaprilat pharmacology, Exercise Test, Male, Mice, Mice, Inbred Strains, Pentolinium Tartrate pharmacology, Pressoreceptors drug effects, Renin-Angiotensin System drug effects, Sympathetic Nervous System drug effects, Telemetry, Hypertension genetics, Hypertension physiopathology, Kidney innervation, Peripheral Nerves physiopathology
- Abstract
Schlager mice (BPH/2J) are hypertensive due to a greater contribution of the sympathetic nervous system (SNS) and renin-angiotensin system (RAS). The kidneys of BPH/2J are hyper-innervated suggesting renal nerves may contribute to the hypertension. We therefore determined the effect of bilateral renal denervation (RD) on hypertension in BPH/2J. Mean arterial pressure (MAP) was measured by radiotelemetry before and for 3 weeks after RD in BPH/2J and BPN/3J. The effects of pentolinium and enalaprilat were examined to determine the contribution of the SNS and RAS, respectively. After 3 weeks, MAP was -10.9 ± 2.1 mmHg lower in RD BPH/2J compared to baseline and -2.1 ± 2.2 mmHg in sham BPH/2J (P < 0.001, n = 8-10). RD had no effect in BPN/3J (P > 0.1). The depressor response to pentolinium was greater in BPH/2J than BPN/3J, but in both cases the response in RD mice was similar to sham. Enalaprilat decreased MAP more in RD BPH/2J compared to sham (-12 vs -3 mmHg, P < 0.001) but had no effect in BPN/3J. RD reduced renal noradrenaline in both strains but more so in BPH/2J. RD reduced renin mRNA and protein, but not plasma renin in BPH/2J to levels comparable with BPN/3J mice. We conclude that renal nerves contribute to hypertension in BPH mice as RD induced a sustained fall in MAP, which was associated with a reduction of intrarenal renin expression. The lack of inhibition of the depressor effects of pentolinium and enalaprilat by RD suggests that vasoconstrictor effects of the SNS or RAS are not involved.
- Published
- 2019
- Full Text
- View/download PDF
26. The gut microbiota and blood pressure in experimental models.
- Author
-
Jama HA, Kaye DM, and Marques FZ
- Subjects
- Animals, Blood Pressure, Diet, Dietary Supplements, Dysbiosis therapy, Humans, Hypertension drug therapy, Hypertension physiopathology, Models, Theoretical, Disease Models, Animal, Dysbiosis complications, Gastrointestinal Microbiome, Germ-Free Life, Hypertension microbiology
- Abstract
Purpose of Review: To summarize evidence supporting that microorganisms colonizing our gastrointestinal tract, collectively known as the gut microbiota, are implicated in the development and maintenance of hypertension in experimental models., Recent Findings: The use of gnotobiotic (germ-free) mice has been essential for advancement in this area: they develop higher blood pressure (BP) if they receive faecal transplants from hypertensive patients compared to normotensive donors, and germ-free mice have a blunted response to angiotensin II. Experimental hypertension is consistently accompanied by changes in the composition of the gut microbiota. This is combined with a shift in microbial diversity and the deterioration of the gut epithelial barrier commonly referred to as gut dysbiosis. Restoration of normal gut biosis and microbiota alleviates and protects against the development of hypertension in both genetic and pharmacological models. This has been achieved by the use of antibiotics, faecal transplants between normotensive and hypertensive strains, and the use of prebiotics (i.e. food stuff that feeds the microbiota), probiotics (i.e. live bacteria) and gut metabolites (i.e. short-chain fatty acids)., Summary: Research into experimental hypertension supports that the gut microbiota contributes to the regulation of BP. Manipulation of the microbiota might represent a new tool to prevent hypertension.
- Published
- 2019
- Full Text
- View/download PDF
27. Population-Based Gut Microbiome Associations With Hypertension.
- Author
-
Jama H, Kaye DM, and Marques FZ
- Subjects
- Cohort Studies, Humans, Gastrointestinal Microbiome, Hypertension
- Published
- 2018
- Full Text
- View/download PDF
28. A polymorphism in the noradrenaline transporter gene is associated with increased blood pressure in patients with resistant hypertension.
- Author
-
Eikelis N, Marques FZ, Hering D, Marusic P, Head GA, Walton AS, Lambert EA, Esler MD, Sari CI, Schlaich MP, and Lambert GW
- Subjects
- Alleles, Drug Resistance, Female, Genotype, Humans, Hypertension drug therapy, Male, Methoxyhydroxyphenylglycol analogs & derivatives, Methoxyhydroxyphenylglycol blood, Middle Aged, Polymorphism, Single Nucleotide, Systole, Blood Pressure genetics, Hypertension genetics, Hypertension physiopathology, Norepinephrine blood, Norepinephrine Plasma Membrane Transport Proteins genetics
- Abstract
Objectives: Noradrenaline released from sympathetic nerves is rapidly inactivated via the action of the noradrenaline transporter (NET). We aimed to determine whether a single nucleotide polymorphism (SNP) in the NET gene, rs7194256, was associated with blood pressure and plasma noradrenaline concentration in patients with resistant hypertension., Methods: Ninety-two consecutive patients with resistant hypertension participated in this study (age 62 ± 1.3 years, BMI 32 ± 0.6 kg/m, mean ± SEM). Blood pressure was assessed using 24-h ambulatory blood pressure monitoring. Genotyping of rs7194256 (C/T) was performed using a predeveloped TaqMan SNP Genotyping Assay. Plasma catecholamines were analyzed using high-performance liquid chromatography., Results: There were no differences in anthropometric measures between those carrying a T allele or the CC genotype. Patients carrying a T allele had significantly higher SBP: 24-h mean 148 ± 2.6 vs. 140 ± 2.4; 24-h max 189 ± 3.2 vs. 179 ± 2.6; 24-h min 114 ± 3.0 vs. 105 ± 2.3; night mean 141 ± 3.0 vs. 131 ± 2.5; night max 170 ± 3.6 vs. 159 ± 3.1; night min 118 ± 3.4 vs. 109 ± 2.4 (all P < 0.05). T-allele carriers had a significantly higher arterial noradrenaline concentration: 573 ± 53 vs. 377 ± 35 pg/ml (P = 0.002) and lower ratio of the intraneuronal noradrenaline metabolite, 3,4-dihydroxyphenylglycol, to noradrenaline (3.01 ± 0.4 vs. 4.08 ± 0.3 pg/ml; P = 0.024)., Conclusion: A SNP in the NET gene in patients with resistant hypertension is associated with higher plasma noradrenaline concentration and elevated SBP. Impaired NET function may be a contributor to the pronounced activation of the sympathetic nervous system characteristic of patients with resistant hypertension.
- Published
- 2018
- Full Text
- View/download PDF
29. Beyond gut feelings: how the gut microbiota regulates blood pressure.
- Author
-
Marques FZ, Mackay CR, and Kaye DM
- Subjects
- Humans, Hypertension diet therapy, Blood Pressure physiology, Diet, Gastrointestinal Microbiome physiology, Hypertension physiopathology
- Abstract
Hypertension is the leading risk factor for heart disease and stroke, and is estimated to cause 9.4 million deaths globally every year. The pathogenesis of hypertension is complex, but lifestyle factors such as diet are important contributors to the disease. High dietary intake of fruit and vegetables is associated with reduced blood pressure and lower cardiovascular mortality. A critical relationship between dietary intake and the composition of the gut microbiota has been described in the literature, and a growing body of evidence supports the role of the gut microbiota in the regulation of blood pressure. In this Review, we describe the mechanisms by which the gut microbiota and its metabolites, including short-chain fatty acids, trimethylamine N-oxide, and lipopolysaccharides, act on downstream cellular targets to prevent or contribute to the pathogenesis of hypertension. These effects have a direct influence on tissues such as the kidney, the endothelium, and the heart. Finally, we consider the role of the gut microbiota in resistant hypertension, the possible intergenerational effect of the gut microbiota on blood pressure regulation, and the promising therapeutic potential of gut microbiota modification to improve health and prevent disease.
- Published
- 2018
- Full Text
- View/download PDF
30. High-Fiber Diet and Acetate Supplementation Change the Gut Microbiota and Prevent the Development of Hypertension and Heart Failure in Hypertensive Mice.
- Author
-
Marques FZ, Nelson E, Chu PY, Horlock D, Fiedler A, Ziemann M, Tan JK, Kuruppu S, Rajapakse NW, El-Osta A, Mackay CR, and Kaye DM
- Subjects
- Animals, Bacteria genetics, Bacteria isolation & purification, Blood Pressure drug effects, Desoxycorticosterone Acetate therapeutic use, Dietary Fiber therapeutic use, Dietary Supplements, Disease Models, Animal, Fibrosis, Gastrointestinal Tract microbiology, Hypertension pathology, Hypertension veterinary, Kidney metabolism, Kidney pathology, Male, Mice, Mice, Inbred C57BL, Myocardium metabolism, Myocardium pathology, Organ Size drug effects, Principal Component Analysis, RNA, Ribosomal, 16S chemistry, RNA, Ribosomal, 16S genetics, RNA, Ribosomal, 16S metabolism, Transcriptome drug effects, Desoxycorticosterone Acetate pharmacology, Dietary Fiber pharmacology, Gastrointestinal Microbiome drug effects, Hypertension prevention & control
- Abstract
Background: Dietary intake of fruit and vegetables is associated with lower incidence of hypertension, but the mechanisms involved have not been elucidated. Here, we evaluated the effect of a high-fiber diet and supplementation with the short-chain fatty acid acetate on the gut microbiota and the prevention of cardiovascular disease., Methods: Gut microbiome, cardiorenal structure/function, and blood pressure were examined in sham and mineralocorticoid excess-treated mice with a control diet, high-fiber diet, or acetate supplementation. We also determined the renal and cardiac transcriptome of mice treated with the different diets., Results: We found that high consumption of fiber modified the gut microbiota populations and increased the abundance of acetate-producing bacteria independently of mineralocorticoid excess. Both fiber and acetate decreased gut dysbiosis, measured by the ratio of Firmicutes to Bacteroidetes, and increased the prevalence of Bacteroides acidifaciens . Compared with mineralocorticoid-excess mice fed a control diet, both high-fiber diet and acetate supplementation significantly reduced systolic and diastolic blood pressures, cardiac fibrosis, and left ventricular hypertrophy. Acetate had similar effects and markedly reduced renal fibrosis. Transcriptome analyses showed that the protective effects of high fiber and acetate were accompanied by the downregulation of cardiac and renal Egr1 , a master cardiovascular regulator involved in cardiac hypertrophy, cardiorenal fibrosis, and inflammation. We also observed the upregulation of a network of genes involved in circadian rhythm in both tissues and downregulation of the renin-angiotensin system in the kidney and mitogen-activated protein kinase signaling in the heart., Conclusions: A diet high in fiber led to changes in the gut microbiota that played a protective role in the development of cardiovascular disease. The favorable effects of fiber may be explained by the generation and distribution of one of the main metabolites of the gut microbiota, the short-chain fatty acid acetate. Acetate effected several molecular changes associated with improved cardiovascular health and function., (© 2016 American Heart Association, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
31. The emerging role of non-coding RNA in essential hypertension and blood pressure regulation.
- Author
-
Marques FZ, Booth SA, and Charchar FJ
- Subjects
- Binding Sites, Blood Pressure physiology, Humans, MicroRNAs blood, MicroRNAs genetics, MicroRNAs urine, Polymorphism, Genetic, Polymorphism, Single Nucleotide, RNA, Long Noncoding genetics, Blood Pressure genetics, Hypertension genetics, RNA, Untranslated genetics
- Abstract
Unravelling the complete genetic predisposition to high blood pressure (BP) has proven to be challenging. This puzzle and the fact that coding regions of the genome account for less than 2% of the entire human DNA support the hypothesis that genetic mechanism besides coding genes are likely to contribute to BP regulation. Non-coding RNAs (ncRNAs) are emerging as key players of transcription regulation in both health and disease states. They control basic functions in virtually all cell types relevant to the cardiovascular system and, thus, a direct involvement with BP regulation is highly probable. Here, we review the literature about ncRNAs associated with human BP and essential hypertension, highlighting investigations, methodology and difficulties arising in the field. The most investigated ncRNAs so far are microRNAs (miRNAs), small ncRNAs that modulate gene expression by posttranscriptional mechanisms. We discuss studies that have examined miRNAs associated with BP in biological fluids, such as blood and urine, and tissues, such as vascular smooth muscle cells and the kidney. Furthermore, we review the interaction between miRNA binding sites and single nucleotide polymorphisms in genes associated with BP. In conclusion, there is a clear need for more human and functional studies to help elucidate the multifaceted roles of ncRNAs, in particular mid- and long ncRNAs in BP regulation.
- Published
- 2015
- Full Text
- View/download PDF
32. microRNAs in Essential Hypertension and Blood Pressure Regulation.
- Author
-
Marques FZ and Charchar FJ
- Subjects
- 3' Untranslated Regions genetics, Animals, Blood Pressure physiology, Disease Models, Animal, Essential Hypertension, Gene-Environment Interaction, Humans, Hypertension physiopathology, Models, Genetic, Blood Pressure genetics, Gene Expression Regulation, Hypertension genetics, MicroRNAs genetics
- Abstract
Unravelling the complete genetic predisposition to high blood pressure (BP) has proven to be challenging. This puzzle and the fact that coding regions of the genome account for less than 2 % of the entire human DNA support the hypothesis that mechanisms besides coding genes are likely to contribute to BP regulation. Non-coding RNAs, especially microRNAs, are emerging as key players of transcription regulation in both health and disease states. They control basic functions in virtually all cell types relevant to the cardiovascular system and, thus, a direct involvement with BP regulation is highly probable. Here we review the literature about microRNAs associated with regulation of BP and hypertension, highlighting investigations, methodology and difficulties arising in the field. These molecules are being studied for exploitation in diagnostics, prognostics and therapeutics in many diseases. There have been some studies that examined biological fluid microRNAs as biomarkers for hypertension, but most remain inconclusive due to the small sample sizes and differences in methodological standardisation. Fewer studies have analysed tissue microRNA levels in vascular smooth muscle cells and the kidney. Others focused on the interaction between single nucleotide polymorphisms and microRNA binding sites. Studies in animals have shown that angiotensin II, high-salt diet and exercise change microRNA levels in hypertension. Treatment of spontaneously hypertensive rats with a miR-22 inhibitor and treatment of hypertensive Schlager BPH/2J mice with a miR-181a mimic decreased their BP. This supports the use of microRNAs as therapeutic targets in hypertension, and future studies should test the use of other microRNAs found in human association studies. In conclusion, there is a clear need of increased pace of human, animal and functional studies to help us understand the multifaceted roles of microRNAs as critical regulators of the development and physiology of BP.
- Published
- 2015
- Full Text
- View/download PDF
33. Measurement of absolute copy number variation reveals association with essential hypertension.
- Author
-
Marques FZ, Prestes PR, Pinheiro LB, Scurrah K, Emslie KR, Tomaszewski M, Harrap SB, and Charchar FJ
- Subjects
- Adult, Blood Pressure genetics, Essential Hypertension, Female, Genotype, Humans, Hypertension physiopathology, Male, Middle Aged, Polymerase Chain Reaction, DNA Copy Number Variations, Genome-Wide Association Study, Hypertension genetics
- Abstract
Background: The role of copy number variation (CNV) has been poorly explored in essential hypertension in part due to technical difficulties in accurately assessing absolute numbers of DNA copies. Droplet digital PCR (ddPCR) provides a powerful new approach to CNV quantitation. The aim of our study was to investigate whether CNVs located in regions previously associated with blood pressure (BP) variation in genome-wide association studies (GWAS) were associated with essential hypertension by the use of ddPCR., Methods: Using a "power of extreme" approach, we quantified nucleic acids using ddPCR in white subjects from the Victorian Family Heart Study with extremely high (n = 96) and low (n = 92) SBP, providing power equivalent to 1714 subjects selected at random., Results: A deletion of the CNVs esv27061 and esv2757747 on chromosome 1p13.2 was significantly more prevalent in extreme high BP subjects after adjustment for age, body mass index and sex (12.6% vs. 2.2%; P = 0.013)., Conclusions: Our data suggests that CNVs within regions identified in previous GWAS may play a role in human essential hypertension.
- Published
- 2014
- Full Text
- View/download PDF
34. A novel interaction between sympathetic overactivity and aberrant regulation of renin by miR-181a in BPH/2J genetically hypertensive mice.
- Author
-
Jackson KL, Marques FZ, Watson AM, Palma-Rigo K, Nguyen-Huu TP, Morris BJ, Charchar FJ, Davern PJ, and Head GA
- Subjects
- Angiotensin-Converting Enzyme Inhibitors pharmacology, Animals, Blood Pressure drug effects, Blood Pressure physiology, Enalaprilat pharmacology, Heart Rate drug effects, Heart Rate physiology, Hypertension blood, Hypertension physiopathology, Mice, Motor Activity drug effects, Motor Activity physiology, Nicotinic Antagonists pharmacology, Pentolinium Tartrate pharmacology, Renin-Angiotensin System drug effects, Sympathetic Nervous System drug effects, Hypertension genetics, MicroRNAs genetics, Renin blood, Renin-Angiotensin System physiology, Sympathetic Nervous System physiopathology
- Abstract
Genetically hypertensive mice (BPH/2J) are hypertensive because of an exaggerated contribution of the sympathetic nervous system to blood pressure. We hypothesize that an additional contribution to elevated blood pressure is via sympathetically mediated activation of the intrarenal renin-angiotensin system. Our aim was to determine the contribution of the renin-angiotensin system and sympathetic nervous system to hypertension in BPH/2J mice. BPH/2J and normotensive BPN/3J mice were preimplanted with radiotelemetry devices to measure blood pressure. Depressor responses to ganglion blocker pentolinium (5 mg/kg i.p.) in mice pretreated with the angiotensin-converting enzyme inhibitor enalaprilat (1.5 mg/kg i.p.) revealed a 2-fold greater sympathetic contribution to blood pressure in BPH/2J mice during the active and inactive period. However, the depressor response to enalaprilat was 4-fold greater in BPH/2J compared with BPN/3J mice, but only during the active period (P=0.01). This was associated with 1.6-fold higher renal renin messenger RNA (mRNA; P=0.02) and 0.8-fold lower abundance of micro-RNA-181a (P=0.03), identified previously as regulating human renin mRNA. Renin mRNA levels correlated positively with depressor responses to pentolinium (r=0.99; P=0.001), and BPH/2J mice had greater renal sympathetic innervation density as identified by tyrosine hydroxylase staining of cortical tubules. Although there is a major sympathetic contribution to hypertension in BPH/2J mice, the renin-angiotensin system also contributes, doing so to a greater extent during the active period and less during the inactive period. This is the opposite of the normal renin-angiotensin system circadian pattern. We suggest that renal hyperinnervation and enhanced sympathetically induced renin synthesis mediated by lower micro-RNA-181a contributes to hypertension in BPH/2J mice.
- Published
- 2013
- Full Text
- View/download PDF
35. Neurogenic hypertension: revelations from genome-wide gene expression profiling.
- Author
-
Marques FZ and Morris BJ
- Subjects
- Animals, Disease Models, Animal, Epigenesis, Genetic, Gene Expression Profiling, Hypertension etiology, Mice, Nitric Oxide metabolism, Oxidative Stress physiology, RNA, Untranslated analysis, RNA, Untranslated physiology, Rats, Rats, Inbred SHR, Reactive Oxygen Species metabolism, Brain metabolism, Brain physiopathology, Hypertension genetics, RNA, Messenger analysis
- Abstract
There is now good evidence for a role of the sympathetic nervous system in the etiology of essential hypertension in humans. Although genetic variation is expected to underlie the elevated sympathetic outflow in this complex polygenic condition, only limited information has emerged from classic molecular genetic studies. Recently, progress has been made in understanding neurogenic aspects by determination of global alterations in gene expression in key brain regions of animal models of neurogenic hypertension. Such genome-wide expression studies in the hypothalamus and brainstem support roles for factors such as neuronal nitric oxide synthase, inflammation and reactive oxygen species. A role for non-coding RNAs such as microRNAs, and epigenetic alterations await exploration. Ongoing novel approaches should provide a better understanding of the processes responsible for the increased sympathetic outflow in animal models, as well as essential hypertension in humans. Such information may lead to better therapies for neurogenic hypertension in humans.
- Published
- 2012
- Full Text
- View/download PDF
36. Letter by Marques and Morris regarding article, "Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection".
- Author
-
Marques FZ and Morris BJ
- Subjects
- Female, Humans, Male, Cytomegalovirus metabolism, Cytomegalovirus Infections blood, Hypertension blood, MicroRNAs blood, RNA, Viral blood
- Published
- 2012
- Full Text
- View/download PDF
37. Gene expression profiling reveals renin mRNA overexpression in human hypertensive kidneys and a role for microRNAs.
- Author
-
Marques FZ, Campain AE, Tomaszewski M, Zukowska-Szczechowska E, Yang YH, Charchar FJ, and Morris BJ
- Subjects
- 3' Untranslated Regions, Adult, Genes, Reporter, Humans, Hypertension metabolism, Kidney Cortex metabolism, Kidney Medulla metabolism, Male, Renin biosynthesis, Gene Expression Profiling, Hypertension genetics, MicroRNAs genetics, MicroRNAs physiology, RNA, Messenger biosynthesis, Renin genetics
- Abstract
The kidney has long been invoked in the etiology of essential hypertension. This could involve alterations in expression of specific genes and microRNAs (miRNAs). The aim of the present study was to identify, at the transcriptome-wide level, mRNAs and miRNAs that were differentially expressed between kidneys of 15 untreated hypertensive and 7 normotensive white male subjects of white European ancestry. By microarray technology we found 14 genes and 11 miRNAs that were differentially expressed in the medulla. We then selected and confirmed by real-time quantitative PCR expression differences for NR4A1, NR4A2, NR4A3, PER1, and SIK1 mRNAs and for the miRNAs hsa-miR-638 and hsa-let-7c. Luciferase reporter gene experiments in human kidney (HEK293) cells confirmed the predicted binding of hsa-let-7c to the 3' untranslated region of NR4A2 mRNA. In the renal cortex we found differential expression of 46 genes and 13 miRNAs. We then confirmed expression differences for AIFM1, AMBP, APOE, CD36, EFNB1, NDUFAF1, PRDX5, REN, RENBP, SLC13A1, STX4, and TNNT2 mRNAs and for miRNAs hsa-miR-21, hsa-miR-126, hsa-miR-181a, hsa-miR-196a, hsa-miR-451, hsa-miR-638, and hsa-miR-663. Functional experiments in HEK293 cells demonstrated that hsa-miR-663 can bind to the REN and APOE 3' untranslated regions and can regulate REN and APOE mRNA levels, whereas hsa-miR-181a regulated REN and AIFM1 mRNA. Our data demonstrated for the first time that miRNAs can regulate renin expression. The observed downregulation of 2 miRNAs in hypertension could explain the elevation in intrarenal renin mRNA. Renin, CD36, and other mRNAs, as well as miRNAs and associated pathways identified in the present study, provide novel insights into hypertension etiology.
- Published
- 2011
- Full Text
- View/download PDF
38. Global identification of the genes and pathways differentially expressed in hypothalamus in early and established neurogenic hypertension.
- Author
-
Marques FZ, Campain AE, Davern PJ, Yang YH, Head GA, and Morris BJ
- Subjects
- Age Factors, Animals, Cytoplasmic Dyneins metabolism, Intracellular Signaling Peptides and Proteins metabolism, Mice, Neuropeptide Y genetics, Neuropeptides metabolism, Oligonucleotide Array Sequence Analysis, Orexins, Oxidative Stress genetics, Polymerase Chain Reaction, Pro-Opiomelanocortin genetics, Receptors, G-Protein-Coupled metabolism, Gene Expression Profiling methods, Gene Expression Regulation genetics, Genes genetics, Hypertension metabolism, Hypothalamus metabolism, Quantitative Trait Loci genetics
- Abstract
The hypothalamus has an important etiological role in the onset and maintenance of hypertension and stress responses in the Schlager high blood pressure (BP) (BPH/2J) mouse, a genetic model of neurogenic hypertension. Using Affymetrix GeneChip Mouse Gene 1.0 ST Arrays we identified 1,019 hypothalamic genes whose expression differed between 6 wk old BPH/2J and normal BP (BPN/3J) strains, and 466 for 26 wk old mice. Of these, 459 were in 21 mouse BP quantitative trait loci. We validated 46 genes by qPCR. Gene changes that would increase sympathetic outflow at both ages were: Dynll1 encoding dynein light chain LC8-type 1, which physically destabilizes neuronal nitric oxide synthase, decreasing neuronal nitric oxide, and Hcrt encoding hypocretin and Npsr1 encoding neuropeptide S receptor 1, each involved in sympathetic response to stress. At both ages we identified genes for inflammation, such as CC-chemokine ligand 19 (Ccl19), and oxidative stress. Via reactive oxygen species generation, these could contribute to oxidative damage. Other genes identified could be responding to such perturbations. Atp2b1, the major gene from genome-wide association studies of BP variation, was underexpressed in the early phase. Comparison of profiles of young and adult BPH/2J mice, after adjusting for maturation genes, pointed to the proopiomelanocortin-α gene (Pomc) and neuropeptide Y gene (Npy), among others, as potentially causative. The present study has identified a diversity of genes and possible mechanisms involved in hypertension etiology and maintenance in the hypothalamus of BPH/2J mice, highlighting both common and divergent processes in each phase of the condition.
- Published
- 2011
- Full Text
- View/download PDF
39. Genes influencing circadian differences in blood pressure in hypertensive mice.
- Author
-
Marques FZ, Campain AE, Davern PJ, Yang YH, Head GA, and Morris BJ
- Subjects
- Animals, Cluster Analysis, Gene Expression Profiling, Gene Expression Regulation, Gene Regulatory Networks genetics, Hypothalamus metabolism, Mice, Polymerase Chain Reaction, Reproducibility of Results, Blood Pressure genetics, Circadian Rhythm genetics, Hypertension genetics, Hypertension physiopathology
- Abstract
Essential hypertension is a common multifactorial heritable condition in which increased sympathetic outflow from the central nervous system is involved in the elevation in blood pressure (BP), as well as the exaggerated morning surge in BP that is a risk factor for myocardial infarction and stroke in hypertensive patients. The Schlager BPH/2J mouse is a genetic model of hypertension in which increased sympathetic outflow from the hypothalamus has an important etiological role in the elevation of BP. Schlager hypertensive mice exhibit a large variation in BP between the active and inactive periods of the day, and also show a morning surge in BP. To investigate the genes responsible for the circadian variation in BP in hypertension, hypothalamic tissue was collected from BPH/2J and normotensive BPN/3J mice at the 'peak' (n = 12) and 'trough' (n = 6) of diurnal BP. Using Affymetrix GeneChip® Mouse Gene 1.0 ST Arrays, validation by quantitative real-time PCR and a statistical method that adjusted for clock genes, we identified 212 hypothalamic genes whose expression differed between 'peak' and 'trough' BP in the hypertensive strain. These included genes with known roles in BP regulation, such as vasopressin, oxytocin and thyrotropin releasing hormone, as well as genes not recognized previously as regulators of BP, including chemokine (C-C motif) ligand 19, hypocretin and zinc finger and BTB domain containing 16. Gene ontology analysis showed an enrichment of terms for inflammatory response, mitochondrial proton-transporting ATP synthase complex, structural constituent of ribosome, amongst others. In conclusion, we have identified genes whose expression differs between the peak and trough of 24-hour circadian BP in BPH/2J mice, pointing to mechanisms responsible for diurnal variation in BP. The findings may assist in the elucidation of the mechanism for the morning surge in BP in essential hypertension.
- Published
- 2011
- Full Text
- View/download PDF
40. Meta-analysis of genome-wide gene expression differences in onset and maintenance phases of genetic hypertension.
- Author
-
Marques FZ, Campain AE, Yang YH, and Morris BJ
- Subjects
- Age of Onset, Animals, Energy Metabolism genetics, Fatty Acids metabolism, Hypertension physiopathology, Lipids physiology, Models, Genetic, Oligonucleotide Array Sequence Analysis, Oxidative Phosphorylation, Rats, Rats, Inbred SHR, Gene Expression Regulation, Genome-Wide Association Study, Hypertension genetics
- Abstract
Gene expression differences accompany both the onset and established phases of hypertension. By an integrated genome-transcriptome approach we performed a meta-analysis of data from 74 microarray experiments available on public databases to identify genes with altered expression in the kidney, adrenal, heart, and artery of spontaneously hypertensive and Lyon hypertensive rats. To identify genes responsible for the onset of hypertension we used a statistical approach that sought to eliminate expression differences that occur during maturation unrelated to hypertension. Based on this adjusted fold-difference statistic, we found 36 genes for which the expression differed between the prehypertensive phase and established hypertension. Genes having possible relevance to hypertension onset included Actn2, Ankrd1, ApoE, Cd36, Csrp3, Me1, Myl3, Nppa, Nppb, Pln, Postn, Spp1, Slc21a4, Slc22a2, Thbs4, and Tnni3. In established hypertension 102 genes exhibited altered expression after Bonferroni correction (P<0.05). These included Atp5o, Ech1, Fabp3, Gnb3, Ldhb, Myh6, Lpl, Pkkaca, Vegfb, Vcam1, and reduced nicotinamide-adenine dinucleotide dehydrogenases. Among the genes identified, there was an overrepresentation of gene ontology terms involved in energy production, fatty acid and lipid metabolism, oxidation, and transport. These could contribute to increases in reactive oxygen species. Our meta-analysis has revealed many new genes for which the expression is altered in hypertension, so pointing to novel potential causative, maintenance, and responsive mechanisms and pathways.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.